Related Experiment Video
Updated: Aug 8, 2026
05:04
Enhancing the Development and Growth of Infant Cerebral Palsy Rats Using Selective Spinal Manipulations
Published on: February 2, 2024
Pediatric Ataxia and Emerging Treatments
Heather Brown1, Kristin Barañano2
1Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Pediatric Neurology
|August 6, 2026
Summary
Pediatric ataxia presents diversely. Current treatments focus on managing complications and supportive care, as disease-modifying therapies for chronic pediatric ataxia are still developing.
Area of Science:
- Neurology
- Pediatrics
- Genetics
Background:
- Pediatric ataxia encompasses various presentations, including chronic and progressive forms.
- Diagnostic strategies for these complex neurological disorders are crucial.
Purpose of the Study:
- To review diagnostic approaches for chronic/progressive pediatric ataxias.
- To provide an overview of emerging and pipeline disease-modifying therapies.
- To highlight current management strategies and supportive care.
Main Methods:
- Literature review of diagnostic strategies for pediatric ataxia.
- Review of current and emerging treatment options.
- Analysis of survivorship data and management recommendations.
Main Results:
- Diagnostic strategies for chronic/progressive pediatric ataxias were reviewed.
- Emerging treatments and disease-modifying therapy pipelines were outlined.
- Survivorship in pediatric ataxia has not significantly improved, emphasizing complication management.
Conclusions:
- Focus remains on managing long-term complications in pediatric ataxia.
- Multidisciplinary team approach and palliative care are essential.
- Development of disease-modifying therapies is ongoing but not yet impactful on survival.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...